NEXVIAZYME
NEXVIAZYME is the first new enzyme replacement therapy for late-onset Pompe disease (LOPD) in 15 years. It’s designed to bind to muscle cells with a high affinity (a strong attachment). After this happens, NEXVIAZYME enters the cells, so it can help break down glycogen.
Administration and Dosage:
NEXVIAZYME is given every 2 weeks by intravenous (IV) infusion. The recommended dosage of NEXVIAZYME is either 20 mg or 40 mg for each kilogram of body weight—your healthcare provider will calculate the appropriate dosage for you. The infusion usually takes approximately 4-5 hours for those receiving 20 mg/kg and approximately 5-7 hours for those receiving 40 mg/kg. There could be additional time if you need any pretreatment. Also, infusion times may vary based on your response to therapy and comfort. Your healthcare provider will give you more details about what to expect during and after your infusion as well as how to prepare.
Indication:
NEXVIAZYME (avalglucosidase alfa-ngpt) is used for the treatment of patients 1 year of age and older with late-onset Pompe disease [lysosomal acid alpha-glucosidase (GAA) deficiency].
Common Side Effects:
The most common side effects reported by people receiving NEXVIAZYME were headache, fatigue, diarrhea, nausea, joint pain, dizziness, muscle pain, itching, vomiting, shortness of breath, rash, “pins-and-needles” sensation, and hives.
More information:
Please see full Prescribing Information including Patient Information.
HAVE QUESTIONS?
